1182913-23-0 Usage
Uses
Used in Pharmaceutical Industry:
4-Bromo-N-isopropyl-3-methylbenzenesulfonamide is used as a pharmaceutical intermediate for the synthesis of various drugs, particularly in the development of potential antifungal and antibacterial agents. Its unique structure, including a benzene ring with a bromine atom and a sulfonamide group, as well as the isopropyl and methyl groups, makes it a versatile and valuable component in drug development.
Used in Medicinal Chemistry Research:
4-Bromo-N-isopropyl-3-methylbenzenesulfonamide is used as a building block in medicinal chemistry research due to its versatile structure and pharmacological properties. The presence of a bromine atom and a sulfonamide group, along with the isopropyl and methyl groups, allows for the exploration of its potential applications in the development of new drugs and therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1182913-23-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,2,9,1 and 3 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1182913-23:
(9*1)+(8*1)+(7*8)+(6*2)+(5*9)+(4*1)+(3*3)+(2*2)+(1*3)=150
150 % 10 = 0
So 1182913-23-0 is a valid CAS Registry Number.
1182913-23-0Relevant academic research and scientific papers
SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING
-
Paragraph 0543, (2019/08/12)
Provided herein are compounds comprising a three-ring core, such as compounds of Formula (X), Formula (X-A), Formula (X-Ai), Formula (X-B), Formula (X-Bi), Formula (Z), Formula (Z-A), Formula (Z-Ai), Formula (Z-B), Formula (Z-Bi), Formula (I), Formula (I-A), Formula (I-Ai), Formula (I-B), and Formula (I-Bi), and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using these compounds, or pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.
